Beijing Biostar To Ride HK IPO To Progress Lead Asset In 2L NSCLC

 
• By Dexter Jie Yan
  
chemotherapy
Beijing Biostar is looking for a global partner to take its novel chemo drug utidelone outside of China. (Shutterstock)

More from Financing

More from Focus On Asia